420130

JNK Inhibitor III, Cell-Permeable

The JNK Inhibitor III, Cell-Permeable controls the biological activity of JNK. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

• Sinónimos: JNK Inhibitor III, Cell-Permeable, SAPK Inhibitor III, HIV-TAT_47-57-gaba-c-Junδ_33-57, Ac-YGRKKRRQRRR-gaba-ILKQSMTLNLADPVGSLKPHLRAKN-NH₂, SAPK Inhibitor III, HIV-TAT_47-57-gaba-c-Junδ_33-57, Ac-YGRKKRRQRRR-gaba-ILKQSMTLNLADPVGSLKPHLRAKN-NH₂
• Fórmula empírica (notación de Hill): C₁₉₁H₃₃₆N₇₀O₄₈S
• Peso molecular: 4413.22
• NACRES: NA.77
• UNSPSC Code: 12352202

Propiedades

• Nombre del producto: JNK Inhibitor III, Cell-Permeable, The JNK Inhibitor III, Cell-Permeable controls the biological activity of JNK. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
• assay: ≥95% (HPLC)
• form: lyophilized solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze; desiccated (hygroscopic); protect from light
• color: white
• solubility: DMSO: 100 mg/mL; acetic acid: 100 mg/mL
• shipped in: wet ice
• storage temp.: −20°C
• Quality Level: 100

Descripción

Biochem/physiol Actions

Cell permeable: yes

Primary Target
JNK

Product does not compete with ATP.

Reversible: no

Disclaimer

Toxicity: Carcinogenic / Teratogenic (D)

General description

A cell-permeable 37 amino acid peptide constructed by fusing the JNK binding domain sequence (δ) (amino acids 33-57) of human c-Jun to the HIV-TAT transduction domain sequence (amino acids 47-57) with a γ-aminobutyric acid (GABA) spacer. Reported to specifically disrupt c-Jun/JNK complex formation and subsequent phosphorylation and activation of c-Jun by JNK in vitro and in intact cells. Also reported to induce apoptosis in HeLa cells. Mode of inhibition is distinct from that of JNK Inhibitor II (SP600125; Cat. No. 420119), so may complement this inhibitor in JNK pathway studies.

A cell-permeable 37-mer peptide constructed by fusing human c-Jun δ domain (amino acids 33-57) sequence with that of HIV-TAT protein transduction domain (amino acids 47-57) via a γ-aminobutyric acid (GABA) spacer. Shown to specifically disrupt c-Jun/JNK complex formation and the subsequent phosphorylation and activation of c-Jun by JNK both in vitro and in intact cells. Since its mode of inhibition is different than that of JNK Inhibitor II (SP600125; Cat. No. 420119), these two inhibitors can complement each other in JNK signaling pathway studies.

Other Notes

Ac-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-gaba-Ile-Leu-Lys-Gln-Ser-Met-Thr-Leu-Asn-Leu-Ala-Asp-Pro-Val-Gly-Ser-Leu-Lys-Pro-His-Leu-Arg-Ala-Lys-Asn-NH₂

Holzberg, D., et al. 2003. J. Biol. Chem.278, 40213.

Packaging

Packaged under inert gas

Physical form

Supplied as a trifluoroacetate salt.

Preparation Note

Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 1
• flash_point_f: Not applicable
• flash_point_c: Not applicable